BIOGRAPHICAL SKETCH Provide the following information for the Senior/key personnel and other significant contributors in the order listed on Form Page 2. Follow this format for each person. DO NOT EXCEED FOUR PAGES. NAME POSITION TITLE KANE, Christopher J Professor of Surgery and Chief of Urology eRA COMMONS USER NAME (credential, e.g., agency login) cjkane EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, include postdoctoral training and residency training if applicable.) DEGREE INSTITUTION AND LOCATION MM/YY FIELD OF STUDY (if applicable) University of California, Davis Uniformed Services University of the Health Sciences, Bethesda, MD University of California, Davis East Bay Surgery Residency, Oakland, CA Oakland Naval Hospital, CA BS MD 1981-1985 1985-1989 Mechanical Engineering Medicine 1989-1990 1992-1995 Surgical Internship Urology Residency A. Personal Statement My research interests are primarily prostate cancer and kidney cancer risk assessment and outcomes. I am currently collaborating with the world-renowned lab of Dr. Michael Karin, Dr. Christina Jamieson and Dr. Steve Howell, designing studies to examine the inhibition of B-cell recruitment and CXCL13/CXCR5 signaling in prostate cancer. We are particularly interested in translating the remarkable discoveries of the Karin lab into meaningful therapeutics for men with prostate cancer. My surgical expertise is in robot-assisted prostatectomy, open and laparoscopic kidney cancer surgery, and bladder and testes cancer surgery. I am one of the most experienced prostate cancer surgeons in California, performing over 150 radical prostatectomies annually. I have taught laparoscopy and robotic surgery extensively, started the robotic surgery programs at UC San Francisco and the VA Medical Center San Francisco, and significantly expanded the robotic surgery program at UC San Diego. B. Positions and Honors Positions 1995-2001 Staff Urologist, Naval Medical Center San Diego 1996-2001 Principal Investigator, Center for Prostate Disease Research 1998-2001 Residency Director, Urology, Naval Medical Center San Diego 1995-1997 Clinical Instructor of Surgery, Uniformed Services University (USUHS) 1997-2001 Assistant Professor of Surgery, Uniformed Services University (USUHS) 2001-2007 Associate Professor of Urology, University of California, San Francisco 2001-2007 Chief of Urology, VA Medical Center San Francisco 7/2007-8/2007 Professor of Urology, UC San Francisco 9/2007-present Professor of Surgery and Urology Residency Program Director, UCSD School of Medicine 9/2007-present Chief of Urology, UC San Diego Health System 2008-present Director of Robotic Surgery, UC San Diego Health System 2008-present GU Oncology Team Leader, UC San Diego Moores Comprehensive Cancer Center 2011-present C. Lowell and JoEllen Parsons Endowed Chair in Urology, UCSD School of Medicine 2012-present Vice Chief of Staff, UCSD Medical Staff Honors (selected) 1998 Navy Commendation Medal (Urology Residency Leadership) 2001 Meritorious Service Medal (Hospital Wide and National Navy Leadership) 2007 William Smart Teaching Award for Outstanding Faculty Teacher in the Department of Urology, University of California, San Francisco 2009 Examination Committee Member for the American Board of Urology 2009-2011 San Diego’s Top Doctors, San Diego Magazine (with San Diego Medical Society) 2010 Physician Healthcare Champion of the Year for San Diego, San Diego Business Journal 2011 Reviewer Roll of Honor, British Journal of Urology, International 2011 Distinguished Engineering Alumni Medal, UC Davis College of Engineering 2011 Top Urologists, U.S. News & World Report C. Selected Peer-Reviewed Publications (15 most relevant from more than 185) 1. Cooperberg MR, Freedland SJ, Pasta DJ, Elkin EP, Presti JC Jr, Amling CL, Terris MK, Aronson WJ, Kane CJ, Carroll PR. Multi-institutional validation of the UCSF Cancer of the Prostate Risk Assessment for prediction of recurrence after radical prostatectomy. Cancer 2006;107(10):2384-2391. 2. Bent S, Kane C, Shinohara K, Neuhaus J, Hudes ES, Goldberg H, Avins AL. Saw palmetto for benign prostatic hyperplasia. N Engl J Med. 2006 Feb 9;354(6):557-66. 3. Boorjian S, Cowan JE, Konety BR, Duchane J, Tewari A, Carroll PR, Kane CJ; Cancer of the Prostate Strategic Urologic Research Endeavor Investigators. Bladder cancer incidence and risk factors in men with prostate cancer: results from Cancer of the Prostate Strategic Urologic Research Endeavor. J Urol. 2007;177(3):883-888. 4. Bastian PJ, Gonzalgo ML, Aronson WJ, Terris MK, Kane CJ, Amling CL, Presti JC Jr, Mangold LA, Humphreys E, Epstein JI, Partin AW, Freedland SJ. Clinical and pathologic outcome after radical prostatectomy for prostate cancer patients with a preoperative Gleason sum of 8 to 10. Cancer. 2006;107:1265-1272. 5. Kane CJ, Presti JC Jr, Amling CL, Aronson WJ, Terris MK, Freedland SJ; SEARCH Database Study Group. Changing nature of high-risk patients undergoing radical prostatectomy. J Urol. 2007;177(1):113-117. 6. Bañez LL, Hamilton RJ, Partin AW, Vollmer RT, Sun L, Rodriguez C, Wang Y, Terris MK, Aronson WJ, Presti JC Jr, Kane CJ, Amling CL, Moul JW, Freedland SJ. Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer. JAMA. 2007;298:2275-2280. 7. Davies BJ, Walsh TJ, Ross PL, Knight SJ, Sadetsky N, Carroll PR, Kane CJ. Effect of BMI on Primary Treatment of Prostate Cancer. Urology. 2008;72(2):406-411. 8. Breyer BN, Greene KL, Dall’Era MA, Davies BJ, Kane CJ. Pelvic Lymphadenectomy in Prostate Cancer. Prostate Cancer Prostatic Dis. 2008;11(4):320-324. 9. Nelles JL, Freedland SJ, Presti JC Jr, Terris MK, Aronson WJ, Amling CL, Kane CJ. Impact of nerve sparing on surgical margins and biochemical recurrence: results from the SEARCH database. Prostate Cancer Prostatic Dis. 2009;12(2):172-176. 10. Kane CJ, Im R, Amling CL, Presti JC Jr, Aronson WJ, Terris MK, Freedland SJ. Outcomes after radical prostatectomy among men who are candidates for active surveillance: results from the SEARCH database. Urology. 2010;76(3):695-700. 11. Silberstein JL, Parsons JK, Palazzi-Churas K, Downs TM, Sakamoto K, Derweesh IH, Woldrich J, Kane CJ. Robot-assisted laparoscopic radical prostatectomy in men with human immunodeficiency virus. Prostate Cancer Prostatic Dis. 2010;13(4):328-332. 12. Hamilton RJ, Banez LL, Aronson WJ, Terris MK, Platz EA, Kane CJ, Presti JC Jr, Amling CL, Freedland SJ. Statin medication use and the risk of biochemical recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) Database. Cancer. 2010;116(14):3389-3398. 13. Raheem O, Kulidjian AA, Wu C, Jeong YB, Yamaguchi T, Smith KM, Goff D, Leu H, Morris SR, Cacalano NA, Masuda K, Jamieson CH, Kane CJ, Jamieson CA. A novel patient-derived intra-femoral xenograft model of bone metastatic prostate cancer that recapitulates mixed osteolytic and osteoblastic lesions.J Transl Med. 2011;9:185198. 14. Kopp RP, Stroup SP, Schroeck FR, Freedland SJ, Millard F, Terris MK, Aronson WJ, Presti JC, Amling CL, Kane CJ. Are repeat prostate biopsies safe? A cohort analysis from the SEARCH database. J Urol. 2012 187(6):2056–2060. 15. Stroup SP, Kane CJ. Robot-assisted laparoscopic prostatectomy for high-risk prostate cancer: technical considerations and review of the literature. ISRN Urol. 2011; 7 pages [Epub Sept 25; PubMed PMID: 22084791]. D. Research Support Ongoing Research Support Astellas/Protocol 905-UC-050 (Kane C) 10/17/2011 – present 0.0 Calendar Astellas Pharmaceuticals $5,266 A Randomized, Double-Blind, Parallel, Placebo-Controlled, Phase 4, Multi-center Study to Assess Efficacy and Safety of VESIcare® (Solifenacin Succinate) to Improve Urinary Continence of Subjects after Robotic Assisted Radical Prostatectomy Major goals: To explore the effectiveness and safety of the United States Food and Drug Administration (FDA) approved drug VESIcare® (Solifenacin Succinate) compared to placebo (inactive drug) on post prostatectomy incontinence; in patients who have recently undergone a robotic-assisted radical prostatectomy. CALGB 90203 (Millard F) NIH/NCI – Cancer and Leukemia Group B 05/17/2007 – present $22,000 0.0 Calendar Role: Sub-Investigator A Randomized Phase III Study of Neo-Adjuvant Docetaxel and Androgen Deprivation Prior to Radical Prostatectomy versus Immediate Radical Prostatectomy in Patients with High-Risk, Clinically Localized Prostate Cancer Major goals: To determine whether treatment with neoadjuvant docetaxel and androgen deprivation therapy prior to radical prostatectomy will increase the rate of 3-year biochemical progression-free survival (bPFS) compared to treatment with immediate radical prostatectomy alone for high-risk prostate cancer patients. Reimbursement: $2,000/patient Phi Delta Psi Charity Trust (Jamieson C) 07/01/2012 – 03/31/2013 0.0 Calendar Phi Delta Psi Charity Trust $60,000 Bone-niche and Castration-resistant Prostate Cancer Role: Co - Principal Investigator Major goals: To develop novel in vivo and in vitro models for castration-resistant prostate cancer in the bone niche using primary prostate cancers and bone metastases to identify biomarkers and targets for molecular therapy. No salary may be supported with this award. 1R01EB014929 - 01A1 (Nguyen Q) 07/01/2012 – 06/30/2017 0.6 Calendar NIH - National Institute of Biomedical Imaging and Bioengineering $250,000 Testing Fluorescently Labeled Probes for Nerve Imaging during Surgery Role: Co-Investigator Major goals: To develop novel fluorescent peptides to visualize nerves in situ during surgery including nerve-sparing prostatectomy. Pfizer (Karin M) 07/01/2012 – 06/30/2015 0.0 Calendar Pfizer $750,000 Inhibition of B cell Recruitment and CXCL13/CXCR5 Signaling in Prostate Cancer Role: Clinical Collaborator Major goals: To determine the utility of CXCR5 blockade in castrate-resistant prostate cancer. Completed Funding Agency: UCSD Moores Cancer Center Translational Cancer Research Funding Period: 4/15/11 – 4/14/12 Title: Robotic Sentinel Lymph Node Mapping via Detection of a Receptor-Targeted Molecular Imaging Probe Role: Co–Principal Investigator Funding Agency: NIH Funding Period: 2005-2010 Title: Evaluation of predictive signatures of prostate cancer. (PI: Wang-Rodriguez, J.) Role: Co-Investigator Goals: To develop a complete and comprehensive clinical data set of patients with a diagnosis of prostate carcinoma and to correlate molecular biomarkers with clinical outcome. Funding Agency: VA Cooperative Group, CSP 407, PIVOT Trial Funding Period: 1995-2007 Title: A randomized trial comparing radical prostatectomy versus palliative expectant management for the treatment of clinically localized prostate cancer. Role: Site PI Goals: The primary objective of this study is to determine which of two strategies is superior for the management of clinically localized prostate cancer: 1) radical prostatectomy with early aggressive intervention for disease persistence or recurrence, 2) expectant management with reservation of therapy for palliative treatment of symptomatic or metastatic disease progression. Funding Agency: VA Cooperative Group, CSP 553 Funding Period: 2006-2007 Title: Chemotherapy after prostatectomy for high risk prostate cancer. Role: Site PI Goals: To prospectively evaluate the efficacy of early adjuvant chemotherapy using docetaxel and prednisone added to the standard of care for patients who are potentially cured by radical prostatectomy but who are at high risk for relapse. Funding Agency: Southwest Oncology Group Funding Period: 7/25/01-2007 Title: Selenium and vitamin E cancer prevention trial. Role: Site PI Goals: To determine whether selenium, vitamin E, or both prevent prostate cancer.